

TXMD · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

TherapeuticsMD Inc · Healthcare · Drug Manufacturers - Specialty & Generic

LATEST CLOSE

2.06 USD

0.0% latest week

Weekly setup

Weak trend

The weekly trend is not active. Price is -3.3% below the Trend Line and sits at 54.6% of its 52-week range. The latest completed week returned 0.0%, after a -2.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 39/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 12d.

Technical setup score 40/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

2.06 USD

24 Jul 2026

1W RETURN

0.0%

latest completed week

4W RETURN

-2.4%

short-term follow-through

12W RETURN

-0.5%

quarterly tape

TREND BREADTH

57.7%

30 of 52 weeks active

VOLUME RATIO

0.7x

vs 13-week average

What is working

- Price is above Fair Value, showing premium demand versus the model.

What could go wrong

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

0.0%

Latest completed week; four-week move -2.4%.

INDICATOR STACK

32/45

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

Copyright 2026 Sharemaestro · Educational market research · sharemaestro.com

Page 1

Not financial advice. Market and fundamental data may be delayed, incomplete, or inaccurate. See the full disclosure on the final page.

OPTIONS PRESSURE

Bullish

39/100 conviction; expected move 42.2%.

NEWS SENTIMENT

48/100

39 relevant articles in the latest sentiment read.

EVENT RISK


12d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -3.3% below the Trend Line and sits at 54.6% of its 52-week range. The latest completed week returned 0.0%, after a -2.4% four-week move.




02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



Demand beneath price

Activity pressure and institutional-style signals


These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.



03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is -2.4% over four weeks, -0.5% over 12 weeks, and 73.1% over one year. The current trend has remained active for 0 consecutive weeks.



Technical setup scorecard

Trend		32
Momentum		44
Activity Pressure		45
Relative Leadership		66
Next-Week Expectancy		50
Volume		27
Smart Money		47
Risk Control		9

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 31 Dec 2025 Financial reporting period used.	FIELD COVERAGE 88% Available factor fields.	MODEL CONFIDENCE 84% Snapshot confidence.
--	--	--	--

Relative factor standing Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.		
Overall factor strength		33/100
Value		42/100
Quality		41/100
Momentum		43/100
Growth		43/100

Valuation How much investors are paying for earnings, sales, and cash flow. P/E 133.2x Price divided by trailing earnings. PRICE / SALES 7.1x Market value relative to trailing revenue. EV / EBITDA - Enterprise value relative to operating cash earnings. FREE-CASH-FLOW YIELD 12.6% Free cash flow as a share of enterprise value.	Business quality Margins and the return generated on invested capital. GROSS MARGIN 90.3% Gross profit retained from each unit of revenue. OPERATING MARGIN -137.8% Operating profit retained from revenue. FREE-CASH-FLOW MARGIN 79.7% Free cash flow generated from revenue. RETURN ON INVESTED CAPITAL -14.2% Operating return generated on invested capital.
--	--

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH82.1%	DIVIDEND YIELD-
Latest one-year revenue growth.	Cash dividends relative to market value.
EPS GROWTH-	BUYBACK YIELD0.0%
Latest one-year earnings-per-share growth.	Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH89.4%	SHAREHOLDER YIELD0.0%
Latest one-year free-cash-flow growth.	Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE6/9	NET DEBT / EBITDA0.8x
Nine-point accounting-strength checklist.	Balance-sheet debt relative to operating cash earnings.

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Bullish

TXMD shows bullish options pressure with a 39/100 conviction score, put-call volume ratio of 0.43, expected move of 42.2%, and Sharemaestro trend signal inactive.

CONVICTION

39/100

Options signal conviction.

EXPECTED MOVE

42.2%

Nearest-chain pricing.

PUT/CALL VOLUME

0.43

Contract volume balance.

Pressure

50

Speculation

15

Volatility

96

Trend agreement

19

Insider activity

-

No recent insider transactions are stored.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

48/100

Weighted news tone is neutral across 39 relevant articles.

9 positive · 23 neutral · 7 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal

Copyright 2026 Sharemaestro · Educational market research · sharemaestro.com

Page 8

Not financial advice. Market and fundamental data may be delayed, incomplete, or inaccurate. See the full disclosure on the final page.

06 · CATALYSTS AND RISK


What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS 12d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.	OPTIONS EXPECTED MOVE 42.2% Nearest-chain priced movement where available.	52-WEEK DRAWDOWN -30.2% Distance below the 52-week high.	13-WEEK VOLATILITY 6.1% Standard deviation of weekly returns.
--	--	--	---

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER 11 of 26 12 weeks finished lower.	BEST WEEK +10.6% Week of 12 Jun.	WORST WEEK -17.2% Week of 30 Jan.	LATEST WEEK +0.0% Week of 24 Jul.
--	--	---	---

Shape of recent returns <table><tr><td>Strong gains</td><td> </td><td>5</td></tr><tr><td>Modest gains</td><td> </td><td>6</td></tr><tr><td>Flat weeks</td><td> </td><td>3</td></tr><tr><td>Modest losses</td><td> </td><td>4</td></tr><tr><td>Sharp losses</td><td> </td><td>8</td></tr></table>	Strong gains		5	Modest gains		6	Flat weeks		3	Modest losses		4	Sharp losses		8	RECENT VOL 6.1% 13-week weekly-return volatility. UP/DOWN SPLIT 25/24 Count of positive and negative weeks in the 52-week window.	BASE VOL 9.7% 52-week weekly-return volatility. AVERAGE SKEW 8.1% / -5.2% Average positive week versus average negative week.
Strong gains		5															
Modest gains		6															
Flat weeks		3															
Modest losses		4															
Sharp losses		8															

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK - / 100 Standing within the tracked group.	GROUP AVERAGE 1.3% Average four-week return.	TREND BREADTH 51.0% Share of peers with an active trend.
---	---	---

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Drug Manufacturers - Specialty & Generic

4-WEEK RANK 36 / 74 Standing within the tracked group.	GROUP AVERAGE -1.2% Average four-week return.	TREND BREADTH 37.8% Share of peers with an active trend.
---	--	---

Peer	Exchange	1W return	4W return	Trend
ZYBT	NASDAQ	147.9%	142.5%	Inactive
TLPH	NASDAQ	1.9%	31.1%	Active
CABR	NASDAQ	11.5%	19.8%	Active
ETON	NASDAQ	0.6%	19.3%	Active
OPTH	NASDAQ	-6.6%	14.4%	Inactive

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	40/100	Trend, activity pressure, participation, and risk combine to a 40/100 tape read.	
Indicator analysis	43/100	Latest 12-week confirmation: trend 5/12, activity pressure 0/12, relative leadership 10/12.	Activity pressure 0.48; No reversal markers
Factors	38/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 52
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	46/100	TXMD shows bullish options pressure with a 39/100 conviction score, put-call volume ratio of 0.43, expected move of 42.2%, and Sharemaestro trend signal inactive.	Bullish · Call-side pressure · Expected move 42.2%
Sentiment	48/100	Weighted news tone is neutral across 39 relevant articles.	TherapeuticsMD Inc. stock outperforms competitors on strong trading day
Insiders	50/100	No recent insider transaction evidence is stored.	Not currently available.
Earnings	12d	Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH 0.0% Latest completed week; four-week move -2.4%.	INDICATOR STACK 32/45 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
OPTIONS PRESSURE Bullish 39/100 conviction; expected move 42.2%.	NEWS SENTIMENT 48/100 39 relevant articles in the latest sentiment read.	EVENT RISK 12d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.	

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	2.06 USD	0.0%	2.13 USD	1.85 USD	-0.34	5.82	122.2K	Off
17 Jul 2026	2.06 USD	3.0%	2.12 USD	1.86 USD	-0.32	4.77	98.8K	Off
10 Jul 2026	2.00 USD	-5.2%	2.11 USD	1.87 USD	-0.41	-1.91	195.4K	Off
03 Jul 2026	2.11 USD	0.0%	2.10 USD	1.89 USD	-0.25	5.81	140.0K	Off
26 Jun 2026	2.11 USD	8.2%	2.09 USD	1.90 USD	-0.39	7.33	168.4K	Off
19 Jun 2026	1.95 USD	-11.4%	2.07 USD	1.91 USD	-0.49	-4.65	226.3K	Off
12 Jun 2026	2.20 USD	10.6%	2.07 USD	1.92 USD	-0.52	10.88	615.9K	On
05 Jun 2026	1.99 USD	-7.0%	2.06 USD	1.94 USD	-0.82	3.20	381.8K	Off
29 May 2026	2.14 USD	0.9%	2.04 USD	1.95 USD	-0.87	6.32	87.1K	On
22 May 2026	2.12 USD	6.0%	2.01 USD	1.96 USD	-0.95	8.44	55.2K	On
15 May 2026	2.00 USD	1.0%	1.98 USD	1.97 USD	-0.96	3.61	81.3K	On
08 May 2026	1.98 USD	-4.3%	1.96 USD	1.99 USD	-0.97	2.20	166.4K	On
01 May 2026	2.07 USD	-5.5%	1.92 USD	2.00 USD	-0.96	12.54	88.5K	On
24 Apr 2026	2.19 USD	5.8%	1.89 USD	2.02 USD	-0.94	21.04	94.7K	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.
Open the live report · Open the interactive chart · Full disclaimer